Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEUROCRINE BIOSCIENCES, INC.

(NBIX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Neurocrine Biosciences : Announces Conference Call and Webcast of Third Quarter 2021 Financial Results

10/11/2021 | 04:02pm EST

SAN DIEGO, Oct. 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter 2021 financial results after the Nasdaq market closes on Monday, November 1, 2021. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Participants can access the live conference call by dialing 800-895-3361 (US) or 785-424-1062 (International) using the conference ID: NBIX. The webcast can also be accessed on Neurocrine's website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn(*in collaboration with AbbVie)

 

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2021-financial-results-301397165.html

SOURCE Neurocrine Biosciences, Inc.


ę PRNewswire 2021
All news about NEUROCRINE BIOSCIENCES, INC.
12:12pOppenheimer Adjusts Neurocrine Biosciences PT to $154 From $140, Maintains Outperform R..
MT
11:39aNeurocrine Biosciences' Positive Huntington Disease Results Should Help Add $300 Millio..
MT
09:23aCitigroup Adjusts Price Target on Neurocrine Biosciences to $129 From $127, Maintains B..
MT
09:13aRBC Lifts Price Target on Neurocrine Biosciences to $122 From $119, Citing 'Positive' H..
MT
12/07Neurocrine Biosciences Says Valbenazine Cuts Chorea in Huntington Disease in Late-Stage..
MT
12/07Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating V..
PR
12/07Neurocrine Biosciences Announces Positive Phase 3 Data
CI
11/30Neurocrine Biosciences Names Jude Onyia Chief Scientific Officer
MT
11/30Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer
PR
11/30Neurocrine Biosciences, Inc. Appoints Jude Onyia, Ph.D., as Chief Scientific Officer
CI
More news
Analyst Recommendations on NEUROCRINE BIOSCIENCES, INC.
More recommendations